People: Delcath Systems Inc (DCTH.PH)

DCTH.PH on Philadelphia Stock Exchange

0.42USD
24 May 2013
Price Change (% chg)

$-0.00 (-0.81%)
Prev Close
$0.42
Open
$0.41
Day's High
$0.43
Day's Low
$0.41
Volume
1,000
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Miao, Graham 

Brief Biography

Mr. Graham G. Miao, M.S., M.B.A., Ph.D., is Chief Financial Officer, Executive Vice President of Delcath Systems, Inc., effective September 26, 2011. Mr. Miao has financial and management experience in global business operations in the United States, Asia and Europe. He most recently served, since 2009, as Chief of Staff of the Global CFO Organization at The Dun & Bradstreet Corporation (NYSE: DNB). From 2007 to 2009, he served as Executive Vice President and Chief Financial Officer of Pagoda Pharmaceuticals Inc., a specialty pharmaceutical and medical device company; and, from 2004-2007, he served as Vice President, Strategic Planning and Financial Analysis, Global Flavors of Symrise Inc, a supplier of flavoring and fragrance products. Prior to joining Pagoda, Mr. Miao was Vice President of Strategic Planning & Financial Analysis at Symrise Inc., a German supplier of flavoring and fragrance products. In this role Mr. Miao served as division-CFO responsible for driving profitable growth of a $700 million business line. Mr. Miao was also Senior Director for Global Primary Care and Global Medical Affairs at Schering-Plough Corporation, serving as the division-CFO for the company’s $3 billion primary care pharmaceuticals franchise. Prior to his time at Schering-Plough, Mr. Miao was at Pharmacia Corporation, serving as Director-Head of Finance for Pharmacia’s $1.3 billion Global Oncology franchise. In this role, he reported operationally to Gabriel Leung, then Head of Global Oncology franchise for Pharmacia and current member of the Delcath Board of Directors. Earlier in his career, Mr. Miao worked as a biotechnology analyst at J.P. Morgan and Company. Mr. Miao earned a Ph.D. in Biological Sciences and an M.B.A. from Columbia University, an M.S. in molecular biology from Arizona State University, and a B.S. in biochemistry from Fudan University in Shanghai, China.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
212,746 -- 256,921 561,917

Options Compensation

  Quantity Market Value
Excercisable -- --
Unexercisable -- --
Excercised -- --
Name Fiscal Year Total

Harold Koplewicz

--

Eamonn Hobbs

1,336,040

Graham Miao

561,917

Peter Graham

567,157

Krishna Kandarpa

506,324

Harold Mapes

--
As Of 30 Dec 2011
Search Stocks